Jazz Pharmaceuticals has entered into a definitive agreement with Redx Pharma to acquire the latter’s KRAS inhibitor program incl. G12D selective and pan-KRAS molecules. Jazz will perform clinical, regulatory, manufacturing & commercialization activities
As per the agreement, Redx will obtain $10M upfront for the rights, patents & title for KRAS inhibitor programs, a payment of $870M on achieving development, regulatory & commercial milestones with an additional milestone of IND clearance plus tiered, mid-single-digit percentage sales-based royalties
Under a separate collaboration agreement, Redx will obtain payment for research and preclinical development for completing IND-enabling studies of both KRAS programs
Ref: Jazz Pharmaceuticals | Image: Jazz Pharmaceuticals
Related News:- Jazz Pharmaceuticals Enters into a 5-Year Research Collaboration Agreement with MD Anderson Cancer Center to Study Zanidatamab in Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
